Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?

Detalles Bibliográficos
Autores principales: Savioli, Felicio, Claro, Maurício, da Silva Ramos, Fernando Jose, Pastore, Laerte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938685/
https://www.ncbi.nlm.nih.gov/pubmed/35306858
http://dx.doi.org/10.1177/10760296221087692
_version_ 1784672598865477632
author Savioli, Felicio
Claro, Maurício
da Silva Ramos, Fernando Jose
Pastore, Laerte
author_facet Savioli, Felicio
Claro, Maurício
da Silva Ramos, Fernando Jose
Pastore, Laerte
author_sort Savioli, Felicio
collection PubMed
description
format Online
Article
Text
id pubmed-8938685
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89386852022-03-22 Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy? Savioli, Felicio Claro, Maurício da Silva Ramos, Fernando Jose Pastore, Laerte Clin Appl Thromb Hemost Letter to the Editor SAGE Publications 2022-03-21 /pmc/articles/PMC8938685/ /pubmed/35306858 http://dx.doi.org/10.1177/10760296221087692 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Letter to the Editor
Savioli, Felicio
Claro, Maurício
da Silva Ramos, Fernando Jose
Pastore, Laerte
Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
title Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
title_full Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
title_fullStr Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
title_full_unstemmed Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
title_short Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
title_sort factor viii, fibrinogen and heparin resistance in covid-19 patients with thromboembolism: how should we manage the anticoagulation therapy?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938685/
https://www.ncbi.nlm.nih.gov/pubmed/35306858
http://dx.doi.org/10.1177/10760296221087692
work_keys_str_mv AT saviolifelicio factorviiifibrinogenandheparinresistanceincovid19patientswiththromboembolismhowshouldwemanagetheanticoagulationtherapy
AT claromauricio factorviiifibrinogenandheparinresistanceincovid19patientswiththromboembolismhowshouldwemanagetheanticoagulationtherapy
AT dasilvaramosfernandojose factorviiifibrinogenandheparinresistanceincovid19patientswiththromboembolismhowshouldwemanagetheanticoagulationtherapy
AT pastorelaerte factorviiifibrinogenandheparinresistanceincovid19patientswiththromboembolismhowshouldwemanagetheanticoagulationtherapy

Ejemplares similares